Risk‑Stratified Chemotherapy and Consolidation Strategies for Neuroblastoma

Overview of Risk‑Based Treatment

The National Comprehensive Cancer Network (NCCN) classifies neuroblastoma therapy by risk group, with markedly different outcomes and treatment intensities between intermediate‑ and high‑risk disease. 2
Overall, current multimodal regimens achieve an approximate 5‑year event‑free survival (EFS) of 51 % in high‑risk patients. 1

Standard chemotherapy: 4–8 cycles of carboplatin, cyclophosphamide, doxorubicin, and etoposide are recommended for intermediate‑risk patients. Category 1 evidence. 3
Response goal: ≥50 % reduction in tumor size is the target endpoint for this regimen. 3
Alternative for suboptimal responders: If the target response is not achieved after 8 cycles, a regimen of cyclophosphamide plus topotecan may be employed. 3
European practice: SIOPEN (European) protocols provide outcomes comparable to the Children’s Oncology Group (COG) strategies for intermediate‑risk disease. 3

ANBL12P1 / ANBL1531 (Category 1 Preferred): a 5‑cycle induction schedule is recommended.
- Cycles 1‑2 – topotecan + cyclophosphamide.
- Cycles 3‑5 – cisplatin combined with alkylator‑intensive agents.
- Efficacy: 80 % of patients achieve a partial response or better at the end of induction.
- Rationale: This regimen reduces nephrotoxic and cardiotoxic exposure compared with older protocols. [1][4]
ANBL0532 (acceptable alternative): a 6‑cycle version using similar agents; provides comparable end‑induction response rates (~80 %). 1
Progression despite intensive induction occurs in ≈9 % of patients, underscoring the need for vigilant response monitoring. 1
The shift from 6‑ to 5‑cycle regimens was driven primarily by toxicity reduction rather than superior efficacy. 1

Tandem Autologous Stem‑Cell Transplant (Category 1 Recommendation):
- First transplant – thiotepa + cyclophosphamide.
- Second transplant (6–10 weeks later) – carboplatin + etoposide + melphalan (dose‑reduced CEM).
- Evidence: The ANBL0532 randomized trial demonstrated a 3‑year EFS of 61.6 % with tandem transplant versus 48.4 % with a single transplant. Level 1 evidence. [5][6]
Single Transplant (reserved for two favorable subgroups):
- Subgroup 1 – Stage L2, age ≥ 18 months at diagnosis, unfavorable histology, MYCN non‑amplified.
- Subgroup 2 – Stage M, age 12 to < 18 months, MYCN non‑amplified, unfavorable features.
- Regimen – full‑dose carboplatin/etoposide/melphalan (CEM). 5
European alternative – busulfan + melphalan (BuMel) showed superior EFS to CEM after rapid COJEC induction in European trials; its role in North America remains investigational, with feasibility demonstrated in an ANBL12P1 pilot. 5

Response‑guided pathway:
- Partial response or better → proceed to consolidation.
- Minor response or stable disease → consider bridging therapy; achieving a complete response after bridging permits continuation to consolidation with favorable outcomes.
- Progressive disease → do not proceed to consolidation; instead use chemo‑immunotherapy with anti‑GD2 monoclonal antibody plus chemotherapy or enroll in a clinical trial. [7][6]
Surgery is deferred until after several cycles of cytoreductive chemotherapy. The goal is gross total resection (>90 % or complete macroscopic removal); subtotal resection is acceptable when vital structures are at risk. [7][4]

Acute toxicities: Nephrotoxicity and cardiotoxicity have been primary drivers for moving toward regimens with reduced platinum and anthracycline exposure. 1
Long‑term toxicities:
- Ototoxicity from platinum agents necessitates routine hearing screening to protect speech and language development.
- Endocrine dysfunction and growth retardation are common after myeloablative therapy.
- Second malignancies occur at an elevated rate in survivors of both high‑ and intermediate‑risk disease. [8][9]

Avoid delays: Consolidation should commence promptly after achieving at least a partial response; tandem transplant benefits are independent of the exact depth of response. 7
Stem‑cell collection must be performed during induction to ensure availability for subsequent high‑dose therapy. [1][4]
Radiotherapy: Consolidative radiotherapy to the primary tumor (and residual metastatic sites in North America) is standard alongside high‑dose chemotherapy. [6][7]

Early incorporation of ALK inhibitors for tumors harboring ALK alterations.
Early administration of ¹³¹I‑MIBG.
Use of anti‑GD2 monoclonal antibody during induction.
All investigational agents should remain confined to clinical trials until robust safety and efficacy data are available. Category 4 (expert opinion) recommendation. [1][4]